Kelly Davio

Alexander Drilon, MD,&nbsp;discussed updated findings with larotrectinib in <em>NTRK</em> fusion&ndash;positive tumors and entrectinib in <em>ROS1</em> fusion&ndash;positive NSCLC.<br /> &nbsp;

The investigational agent avapritinib demonstrated encouraging response rates in patients with advanced gastrointestinal stromal tumors and PDGFR&alpha; D842V-driven GIST, according to findings presented during the 2018 Annual Meeting of the Connective Tissue Oncology Society in Rome, Italy.

Patrick Sch&ouml;ffski, MD, MPH,&nbsp;discussed the key findings from the CREATE trial, the next steps for research into inflammatory myofibroblastic tumor, and the regulatory challenges for approval of drugs for rare cancers.

Bruno Sangro, MD,&nbsp;discusses the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for HCC.

Fabio Piscaglia, MD, discusses the updated 2018&nbsp;European Association for the Study of the Liver clinical guidelines, which were presented during the 12th International Liver Cancer Association Annual Conference in London, United Kingdom.